Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study t

Name: Phase 3 Topline: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study t
Start: 2027-06-30

June 30, 2027

Company: Galmed Pharmaceuticals Ltd. (GLMD)
Drug: open-label
Indication: Nonalcoholic Steatohepatitis (NASH)

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study t — GLMD Phase 3 Readout | BioSniper